PMID- 36719372
OWN - NLM
STAT- MEDLINE
DCOM- 20230202
LR  - 20240106
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 133
IP  - 3
DP  - 2023 Feb 1
TI  - Next-generation antigen-presenting cell immune therapeutics for gliomas.
LID - 10.1172/JCI163449 [doi]
LID - e163449
AB  - Antigen presentation machinery and professional antigen-presenting cells (APCs) 
      are fundamental for an efficacious immune response against cancers, especially in 
      the context of T cell-centric immunotherapy. Dendritic cells (DCs), the gold 
      standard APCs, play a crucial role in initiating and maintaining a productive 
      antigen-specific adaptive immunity. In recent decades, ex vivo-differentiated DCs 
      from circulating CD14+ monocytes have become the reference for APC-based 
      immunotherapy. DCs loaded with tumor-associated antigens, synthetic peptides, or 
      RNA activate T cells with antitumor properties. This strategy has paved the way 
      for the development of alternative antigen-presenting vaccination strategies, 
      such as monocytes, B cells, and artificial APCs, that have shown effective 
      therapeutic outcomes in preclinical cancer models. The search for alternative APC 
      platforms was initiated by the overall limited clinical impact of DC vaccines, 
      especially in indications such as gliomas, a primary brain tumor known for 
      resistance to any immune intervention. In this Review, we navigate the APC immune 
      therapeutics' past, present, and future in the context of primary brain tumors.
FAU - Lee-Chang, Catalina
AU  - Lee-Chang C
AD  - Department of Neurological Surgery, Feinberg School of Medicine, Northwestern 
      University, Chicago, Illinois, USA.
AD  - Malnati Brain Tumor Institute, Chicago, Illinois, USA.
FAU - Lesniak, Maciej S
AU  - Lesniak MS
AD  - Department of Neurological Surgery, Feinberg School of Medicine, Northwestern 
      University, Chicago, Illinois, USA.
AD  - Malnati Brain Tumor Institute, Chicago, Illinois, USA.
LA  - eng
GR  - R37 CA258426/CA/NCI NIH HHS/United States
GR  - P50 CA221747/CA/NCI NIH HHS/United States
GR  - R35 CA197725/CA/NCI NIH HHS/United States
GR  - R01 NS115955/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230201
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Humans
MH  - Dendritic Cells
MH  - Antigen Presentation
MH  - T-Lymphocytes
MH  - *Glioma/therapy
MH  - Immunotherapy
MH  - *Cancer Vaccines
PMC - PMC9888388
COIS- Conflict of interest: The authors have declared that no conflict of interest 
      exists.
EDAT- 2023/02/01 06:00
MHDA- 2023/02/03 06:00
PMCR- 2023/02/01
CRDT- 2023/01/31 10:43
PHST- 2023/02/01 06:00 [pubmed]
PHST- 2023/02/03 06:00 [medline]
PHST- 2023/01/31 10:43 [entrez]
PHST- 2023/02/01 00:00 [pmc-release]
AID - 163449 [pii]
AID - 10.1172/JCI163449 [doi]
PST - epublish
SO  - J Clin Invest. 2023 Feb 1;133(3):e163449. doi: 10.1172/JCI163449.